Skip to main content
. 2015 Nov 17;59(12):7367–7373. doi: 10.1128/AAC.01533-15

FIG 4.

FIG 4

IL-10/TNF-α ratios in sera of healthy, infected mice treated with placebo (control group) and infected mice treated with 6.25 mg/kg of ruxolitinib started 1 day after infection (D+1) and 50 mg/kg of ruxolitinib started 1 day before infection (D−1). Results of one-way analysis of variance are shown together with the posttest for linear trend.